
    
      The study will look at the safety and efficacy of melatonin supplementation given to patients
      with chronic kidney disease and end stage renal disease who have sleep disorders to reduce
      sleep latency times, the number of apnea/hypopneic episodes, and prolong duration in rapid
      eye movement (REM) sleep in CKD and ESRD patients with sleep disordered breathing.
    
  